Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40DEH | ISIN: US09073Q3039 | Ticker-Symbol: 2F5
Tradegate
06.06.25 | 21:20
2,200 Euro
-1,79 % -0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR Chart 1 Jahr
5-Tage-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
2,1802,28006.06.

Aktuelle News zur SCINAI IMMUNOTHERAPEUTICS LTD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoScinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.60The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing...
► Artikel lesen
MoScinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
30.05.Scinai Immunotherapeutics reports Q1 results1
30.05.Scinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn151JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on...
► Artikel lesen
07.05.Scinai Immunotherapeutics Ltd.: Scinai Announces Annual Financial Results for 202444JERUSALEM, May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing...
► Artikel lesen
07.05.Scinai Immunotherapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers3
27.03.Scinai Immunotherapeutics Ltd.: Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions82Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus...
► Artikel lesen
24.03.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
SCINAI IMMUNOTHERAPEUTICS LTD Aktie jetzt für 0€ handeln
11.03.Scinai Immunotherapeutics Ltd. - F-1/A, Registration statement for certain foreign private issuers1
05.03.Scinai Immunotherapeutics announces $10M standby equity purchase agreement1
04.03.Scinai Immunotherapeutics Ltd. - F-1, Registration statement for certain foreign private issuers-
04.03.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
16.12.24Scinai Launches U.S. CDMO to Meet Growing Demand3
22.11.24Scinai Immunotherapeutics Ltd.: Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million158JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing...
► Artikel lesen
29.08.24Scinai Immunotherapeutics Ltd.: Scinai Regains Full Compliance with Nasdaq Listing Requirements157JERUSALEM, Aug. 29, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology...
► Artikel lesen
15.08.24Scinai Immunotherapeutics Ltd.: Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23131JERUSALEM, Aug. 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology...
► Artikel lesen
15.07.24Scinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model190JERUSALEM, July 15, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological...
► Artikel lesen
08.07.24Scinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity280JERUSALEM, July 8, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological...
► Artikel lesen
03.07.24Scinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements145JERUSALEM, July 3, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological...
► Artikel lesen
02.07.24Scinai Immunotherapeutics Ltd.: Scinai Publishes Q1 2024 Financial Results and Provides Business Update141JERUSALEM, July 2, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1